BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200728
DTEND;VALUE=DATE:20200729
DTSTAMP:20200723T185535Z
CREATED:20200711T191810Z
LAST-MODIFIED:20200723T185535Z
UID:21522-1595894400-1595980799@ces.b2sg.org
SUMMARY:Epigenetic Therapeutic Targets
DESCRIPTION:The Epigenetic Therapeutic Targets meeting brings together academic and industry leaders in the field of epigenetics. These include:\n\n  \nSTORM therapeutics / AstraZeneca / GSK / Oryzon Genomics / Incyte / EpiZyme / 4SC / Bluebird Bio / Bristol Myers Squibb / Prelude Therapeutics / Corvidia Therapeutics / Foghorn Therapeutics / Epigeneron / Abcam / Salarius Pharmaceuticals / Twentyeight-Seven Therapeutics / aTyr Pharma / Epitoire / Epic Therapeutics / Constellation Pharmaceuticals / Vertex / Volition / Novartis / Imago Biosciences / Omega Therapeutics / Genentech / Resverlogix Corp / Accent Therapeutics / Johns Hopkins Medicine / Zenith Epigenetics / Imperial College London / Ohio State University / University of Rome La Sapienza / Viracta Therapeutics / Cancer Epigenetics Society / Dovetail Genomics / University of California San Diego \n\nMeeting program:\n\n7:30 am Online speed networking\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n8:00 am Opening Keynote Address: Chromatin-modifying and RNA-modifying Enzyme Inhibitors as Precision Cancer Therapeutics\n\nRobert Copeland\, President\, Chief Scientific Officer and Co-Founder \, Accent Therapeutics\n\n\n\nSynopsis\n\nThe history of epigenetics – from first wave to present day \nBenefits of RNA modifying enzymes as a target \nPrecise combination therapeutics in cancer (including epigenetics) for patients in the future \n\n\n\n\n8:30 am Targeting cancer with first-in-class inhibitors of the RNA m6A methyltransferase METTL3\n\nMark Albertella\, Vice President\, Translational Oncology\, Storm Therapeutics\n\n\n\nSynopsis\n\nIntroduction to RNA modifications\, the role of METTL3 and the m6A modification on selected mRNA species\nOverview of our drug discovery efforts to identify potent and selective inhibitors of METTL3\nCharacterisation of potent\, selective\, bioavailable inhibitors of METTL3 in biochemical\, biophysical and cellular assays\nExploration of utility of METTL3 inhibitors in hematological and solid tumour cell lines\nDemonstration of in vivo activity of METTL3 inhibitors in hematological and solid tumour models\n\n\n\n\n9:00 am From Somatic Mutations to Chromatin Topology – Emerging Tools For Epigenetic Biomarker Discovery\n\nTodd Dickinson\, CEO\, Dovetail Genomics\n\n\n\nSynopsis\n\nIntroduction to Omni-C\, a single assay for SNP detection\, SV mapping and\nchromatin 3-D landscape characterization\nInsights into drug response by capturing the 3-D gene regulatory landscape\nChromatin topology improves cancer genome characterization\nEnhancing bio-marker discoveries with genome topology\n\n\n\n\n9:15 am Overcoming Therapy Resistance to Cancer Immune Therapy – The role of epigenetic modulators\n\nSvetlana Hamm\, Head of Research and Translational Medicine\, 4SC\n\n\n\nSynopsis\n\nCancer immunophenotypes and immune escape mechanisms – how to address resistance to immune checkpoint therapy\nImmunomodulatory features of epigenetic drugs – rationale selection of combinations\, dose\, and schedule\nCase studies: i) Broad-spectrum HDAC inhibitor resminostat in combination with opsonizing antibodies in haematological cancer; ii) Class I HDAC inhibitor domatinostat in combination with checkpoint blockade – translation of preclinical findings into the clinic\n\n\n\n\n9:45 am Modulation of the Lysine Specific Demethylase 1 with iadademstat and vafidemstat: Cancer\, Cognition and Behavior\n\nRobert Soliva\, Drug Discovery Director\, Oryzon Genomics\n\n\n\nSynopsis\n\nInhibition of LSD1 by irreversible binding to the FAD cofactor\nIadademstat for treatment of AML and SCLC\nIncreased of neuronal plasticity and improvement of cognitive and behavioral functions by treatment with vafidemstat\nModulation of LSD1 activity as a personalized medicine strategy in CNS disease.\n\n\n\n\n10:15 am Online speed networking\n\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n10:45 am Epigenetic Dual Targeting Compounds: Together is Better\n\nAntonello Mai\, Professor\, Spienza University of Rome\n\n\n\nSynopsis\n\nThe design and biological validation of compounds able to simultaneously hit two epigenetic targets will be discussed with their effects in cancer diseases\, in comparison with the single-target inhibitors.\n\n\n\n\n11:15 am Automated High-throughput ChIP-seq Workflow using Covaris Adaptive Focused Acoustics® System for Accelerated Epigenetic Drug Screening\n\nAlon Goren\, Assistant Professor\, Department of Medicine\, University of California San Diego\n\n\n\nSynopsis\n\nStreamlining and reduce workflow time using automated ChIP-seq with the Covaris Adaptive Focused Acoustics (AFA)\nEvaluation of the AFA technology in a range of epitopes\, including H3K4me3\, H3K27me3\, H3K27ac\, RNA Pol-II\, CTCF\, and HNF4A in different cell lines.\nHow to utilize AFA-based ChIP-seq processes for rapid epigenetic drug screening and clinical diagnostics\n\n\n\n\n11:30 am Targeting epigenetic adaptation in ovarian cancer\n\nRobert Brown\, Professor\, Imperial College London\n\n\n\nSynopsis\n\nImproving treatment of ovarian cancer is a major clinical unmet need.\nEpigenetic adaptation is a driver of drug resistance in ovarian cancer.\nPotential of histone methyltransferases to overcome drug resistance.\nModulation of the immune microenvironment by histone methyltransferases.\n\n\n\n\n11:50 am The use of epigenetic therapy to improve the efficacy of immune checkpoint therapy for multiple common cancer types\n\nStephen Baylin\, Professor of Oncology\, John Hopkins University\n\n\n\n\n\n12:10 pm Panel: Combination Therapies vs Monotherapies – Approaches with epigenetic therapies\n\nRobert Brown\, Professor\, Imperial College London\nStephen Baylin\, Professor of Oncology\, John Hopkins University\nIM Bennani-Baiti\, President & CEO\, Cancer Epigenetics Society\n\n\n\nSynopsis\n\nCan HDAC inhibitors really work as a monotherapy?\nClinical trial implications of combination therapies\n\n\n\n\n12:40 pm Panel: Our Social Media Feeds Are Personalized – Why Isn’t Our Medical Treatment?\n\nElisabetta Chiarparin\, Director of Oncology Chemistry and Programme Leader\, AstraZeneca\nPeter Atadja\, Director & Head\, Drug Discovery \, Novartis\nRobert Copeland\, President\, Chief Scientific Officer and Co-Founder \, Accent Therapeutics\nRajarshi Choudhury\, Genome Editing Investigator\, GSK\n\n\n\nSynopsis\n\nThe journey to personalized medicine and the role epigenetics will play \nHow to design a drug development pipeline for precision medicine \nThe future of personalised medicine – a pipe dream or legitimate goal? \n\n\n\n\n1:20 pm Online speed networking\n\n\nSynopsis\nAutomated online speed networking – randomized matches made automatically based on profile – 5 rounds of 3 mins – to help people “accidentally meet”. \n\n\n\n1:50 pm Panel: Toxicity and Off-Target Effects\n\nNeil Michaud\, Senior Director\, Translational Medicine\, Epizyme\nPaul Kayne\, Head\, Discovery Genomics & Proteomics\, Bristol-Myers Squibb\nKai He\, Assistant Professor of Medicine The Ohio State\, University College of Medicine\nTamara Maes\, CSO\, VP and founder\, Oryzon Genomics\n\n\n\nSynopsis\n\nOvercoming the obstacles of toxicity regardless of target \nTechniques for monitoring toxicity and balancing this with efficacy \nDebating the dangers of off-target effects versus on-target effects \n\n\n\n\n2:30 pm Case Study: The Tazemetostat Story\n\nNeil Michaud\, Senior Director\, Translational Medicine\, Epizyme\n\n\n\nSynopsis\n\nDesigning a successful clinical trial – balancing efficacy and safety\nPatient cohorts based on a diagnostic tool that identifies patients with specific EZH2 mutations\nFuture implications\, plans and the move towards precision medicine in oncology\n\n\n\n\n3:00 pm Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study\n\nNorman Wong\, Co-Founder and CSO\, Resverlogix Corp\n\n\n\nSynopsis\n\nEpigenetic regulation and BET system in CVD/T2DM\nMechanism of Apabetalone\nHighlights of Pre-clinical and Clinical Data\n\n\n\n\n3:30 pm Targeting SMARCA4-mutant lung cancers through selective\, chemically-induced degradation of SMARCA2\n\nRobert Yauch\, Director & Principal Scientist\, Discovery Oncology\, Genentech\n\n\n\nSynopsis\n\nSMARCA4 is mutationally-inactivated in subsets of lung cancer leading to a dependency on the paralog helicase\, SMARCA2\nThe discovery and development of selective SMARCA2 inhibitors would be essential for therapeutically targeting SMARCA4-mutant lung cancers\nIn vitro characterization and demonstration of in vivo activity of potent and selective degraders of SMARCA2\n\n\n\n\n4:00 pm Targeting cancer therapy with an epigenetic drug: Pre-clinical and clinical experience\n\nRichard Trauger\, Senior Director Translational Medicine\, Viracta Therapeutics\n\n\n\nSynopsis\n\nSpecificity and properties of a compound in relation to clinical application\nCreating an oral drug and a dosing schedule that works\nVirus activation vs HDAC inhibitors\n\n\n\n\n4:30 pm Online Networking break\n\n\nSynopsis\nGrab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking! \n\n\n\n5:00 pm Design of combination strategies and identification of biomarkers associated with clinical response to the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients\n\nEric Campeau\, Senior Director\, Translational Medicine\, Zenith Epigenetics\n\n\n\nSynopsis\n\nOptimal combination agents to use with BET bromodomain inhibitors in the clinic\nPatient populations that can benefit from combinatorial therapies with ZEN-3694\nBiomarkers of response of ZEN-3694 + enzalutamide in mCRPC patients\n\n\n\n\n5:20 pm The antileukemic effect exerted by LSD1 inhibition\n\nHugh Young\, Reinhoff\, CEO\, Imago BioSciences\n\n\n\n\n\n5:40 pm Panel: The Role of Epigenetics in an Oncology Portfolio\n\nMahesh Karande\, President and CEO\, Omega Therapeutics\nSusan Wee\, Senior Director\, Oncology Drug Discovery\, Incyte\nEric Campeau\, Senior Director\, Translational Medicine\, Zenith Epigenetics\nHugh Young\, Reinhoff\, CEO\, Imago BioSciences\n\n\n\nSynopsis\n\nUtilizing epigenetics in combination with immunotherapies to further bolster the immune response\nBuilding a differentiated oncology portfolio based on standalone epigenetic (mono)therapies\nImagining the future of epigenetic therapies in oncology and beyond\n\n\n\n\n6:30 pm Close of virtual conference
URL:https://ces.b2sg.org/event/epigenetic-therapeutic-targets/
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2020/07/Epigenetics-Meeting-July-28_2020.jpg
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191120
DTEND;VALUE=DATE:20191124
DTSTAMP:20190414T135609Z
CREATED:20190414T135609Z
LAST-MODIFIED:20190414T135609Z
UID:21198-1574208000-1574553599@ces.b2sg.org
SUMMARY:Metabolism Meets Epigenetics
DESCRIPTION:Symposium Overview\nMetabolism and epigenetics are intricately linked\, playing a key role in development\, cancer\, immune signalling and ageing. This symposium brings together world-leading researchers exploring this nexus and will focus in particular on how metabolites and metabolic networks impact gene regulation\, on recently discovered roles of metabolites in disease and how this opens novel therapeutic avenues. We will highlight enabling tools linking metabolites\, their localisation within tissues and cells with the regulation of chromatin structure\, gene activity and epigenetic inheritance. \nInnovative molecular and computational tools that enable the detection of metabolites in time and space\, as well as novel biology in powerful model organisms and clinical data have led to a renaissance of research on metabolism\, especially in the context of epigenetics and gene regulation. The goal of our interdisciplinary symposium is to strengthen the connection between these fields\, inspire novel ideas and enable collaborations at this frontier. \nSession Topics\n\n\nMetabolic regulation of epigenetic marks\nMetabolic control of gene expression\nMetabolism in development and disease\nSystems analysis of metabolism\nImmunometabolism\nCancer metabolism\nImmune cell metabolism\nNovel tools for metabolism and epigenetics\n\n\nSpeakers: \nAsifa Akhtar \nMax Planck Institute of Immunobiology and Epigenetics\, Germany \nAlexander Aulehla\, \nEMBL Heidelberg\, Germany  \nGuoliang Cui\nGerman Cancer Research Center\, Germany  \nAnne-Claude Gavin\nEMBL Heidelberg\, Germany  \nKai Johnsson\nMax Planck Institute for Medical Research\, Germany  \nSue Kaech\nSalk Institute for Biological Studies\, USA  \nSusanne Mandrup\nUniversity of Southern Denmark \nAshby Morrison\nStanford University\, USA  \nMihai Netea\nRadboud University Medical Center\, The Netherlands \nJohn O’Neill \nMRC Laboratory of Molecular Biology\, UK  \nPaola  Picotti\nETH Zurich\, Switzerland \nJohn Andrew Pospisilik \nVan Andel Research Institute\, USA \nMarkus Ralser\nThe Francis Crick Institute\, UK &\nCharité -University Medicine\, Germany  \nMatthias Tschöp\nHelmholtz Zentrum München\, Germany  \nBenjamin Tu\nUT Southwestern Medical Center\, USA  \nKathryn  Wellen\nUniversity of Pennsylvania\, USA  \nOscar Yanes \nRovira i Virgili University\, Spain 
URL:https://ces.b2sg.org/event/embo-meeting20nov19/
LOCATION:EMBL Heidelberg\, Meyerhofstraße 1\, Heidelberg\, 69117 \, Germany
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/EMBO_Logo_grey-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191106
DTEND;VALUE=DATE:20191109
DTSTAMP:20190406T230434Z
CREATED:20190403T201519Z
LAST-MODIFIED:20190406T230434Z
UID:21161-1572998400-1573257599@ces.b2sg.org
SUMMARY:Epigenomics of Common Diseases
DESCRIPTION:Discussing the future of epigenomic studies of common diseases\nWe are pleased to announce the 8th Epigenomics of Common Diseases conference and invite scientists working on experimental and computational epigenomics and epigenetics to showcase the latest developments in the field and discuss epigenomic approaches in common human diseases. \nEpigenetic variation plays an important role in disease processes and provides a promising focus for disease prediction\, prevention and treatment. Technological advancements in the past few years have fuelled a dramatic increase in the scale\, breadth and availability of epigenomic reference maps\, including populational and environmental epigenomic datasets. \nThis year’s conference will cover a broad spectrum of epigenomic discoveries\, opportunities\, and also challenges\, in human normal biology and in disease. \nProgramme:  \nThe conference will start at 12.30 on Wednesday\, 6 November and close at 14.00 on Friday\, 8 November 2019. \nTopics will include: \n\nGenetic-epigenetic interactions\nOld and new roles of epigenomic factors\nEpigenomics in development and ageing\nEpigenomic misregulation in cancer\, brain and other diseases\nPopulational and environmental epigenomics\nMethodological challenges: epigenomic study design\, data analysis and interpretation\nThe future of epigenomic studies of common diseases\n\n  \nKeynote speakers \nCheryl Arrowsmith – University of Toronto\, Canada \nJohn Stamatoyannopoulos – University of Washington\, USA \n  \nConfirmed speakers \nDeborah Bourc’his – Institut Curie\, France \nJoseph Costello – UC San Francisco\, USA \nJohn Greally – Albert Einstein College of Medicine\, USA \nEilis Hannon – University of Exeter\, UK \nKristian Helin – Sloan Kettering Institute\, USA \nEva Jablonka – Tel Aviv University\, Israel \nViviane Labrie – Van Andel Institute\, USA \nStephanie London – NIEHS\, USA \nMathieu Lupien – University of Toronto\, Canada \nRaphäel Margueron – Institut Curie\, France \nKyung-Min Noh – EMBL\, Germany \nVardhman Rakyan – Queen Mary University of London\, UK \nClaire Rougeulle – CNRS / Université Paris Diderot\, France \nRichard Saffery – Murdoch Children’s Research Institute\, Australia
URL:https://ces.b2sg.org/event/6-8nov19-epigenomics/
LOCATION:Wellcome Genome Campus\, UK\, Wellcome Trust Genome Campus\, Hinxton\, CB10 1SA\, United Kingdom
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2019/04/ECD_EarlyBird_Twitter.jpg
ORGANIZER;CN="Advanced Courses and Scientific Conferences%2C Wellcome Genome Campus":MAILTO:scientificconferences@wellcomegenomecampus.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190927
DTEND;VALUE=DATE:20191002
DTSTAMP:20181103T153555Z
CREATED:20181103T151702Z
LAST-MODIFIED:20181103T153555Z
UID:20799-1569542400-1569974399@ces.b2sg.org
SUMMARY:ESMO 2019 Congress
DESCRIPTION:ESMO is delighted to announce that the ESMO 2019 annual Congress will take place in partnership with the European Association for Cancer Research (EACR) from 27 September to 1 October 2019\, at the Fira Barcelona\, Spain. \nThe ESMO Congress is the appointment in Europe for clinicians\, researchers\, patient advocates\, journalists and the pharmaceutical industry from all over the world to get together\, learn about the latest advances in oncology and translate science into better cancer patient care. \nESMO 2019 will be the global stage for excellence in translational research\, presentation of practice-changing data and multidisciplinary discussions. \nWe invite you to save the date. \n  \nOnline registration will be available in January 2019
URL:https://ces.b2sg.org/event/esmo2019/
LOCATION:Gran Via venue\, Av. Joan Carles I\, 64\, Barcelona\, 08908\, Spain
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2018/11/2019_esmo_inevidenza-e1541241108833.png
ORGANIZER;CN="Chantal Cornu%2C Valentina Allevato":MAILTO:congress@esmo.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190720
DTEND;VALUE=DATE:20190722
DTSTAMP:20190414T144413Z
CREATED:20190414T144212Z
LAST-MODIFIED:20190414T144413Z
UID:21200-1563580800-1563753599@ces.b2sg.org
SUMMARY:Dynamics of Epigenetic Regulation: Mechanisms and Beyond
DESCRIPTION:The Gordon Research Seminar on Epigenetics is a unique forum for graduate students\, postdocs\, and other junior scientists to present and exchange new data and cutting-edge ideas. The focus of this meeting is on recent advances in our understanding of the dynamic nature of epigenetic regulatory mechanisms across phyla. In particular\, we will focus on how epigenetic alterations can influence phenotypic plasticity\, development\, reprogramming\, and transgenerational inheritance. The GRS will include a keynote address by Dr. Bradley Cairns\, as well as a career panel discussion with panelists from academic and non-academic fields. \nApplication Instructions\nThe seminar will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS\, either by giving an oral presentation or presenting a poster. Therefore\, all applications must include an abstract. \nThe seminar chair will select speakers from abstracts submitted by April 20\, 2019. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate\, you must submit an application by the date indicated in the Application Information section above. \nProgram Format\nGordon Research Seminars are 2-day meetings which take place on the Saturday and Sunday just prior to the start of the associated GRC. The GRS opens with a 1-hour introductory session on Saturday afternoon\, followed by a poster session\, dinner and a 2-hour session in the evening. Sunday morning begins with breakfast and is followed by another 2-hour session\, a second poster session\, and lunch. A final 1-hour session takes place just after lunch\, and the associated GRC begins later that evening. \nAn outline of the program components for this GRS is displayed below. The seminar chair is currently developing their detailed program schedule\, which will include the speakers they select from submitted abstracts\, in addition to any additional components outlined below. The detailed program will be available by May 20\, 2019. Please check back for updates. \n\nKeynote Speaker\n\n\n\nBradley Cairns (University of Utah\, USA)\n\n\n\nSpeakers\n\n\n\nTo Be Selected from Submitted Abstracts\n\n\n\nDiscussion Leaders\n\n\n\nJulie Ahringer (University of Cambridge\, United Kingdom)\nAmander Clark (University of California\, Los Angeles\, USA)\n\n\n\n\nAdditional Discussion Leaders May Be Selected from Submitted Abstracts\n\n  \nApplications for this meeting must be submitted by June 22\, 2019. Please apply early\, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed\, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the conference chair if more seats become available due to cancellations. \nGRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above\, any applicants who wish to be considered for an oral presentation should submit their application by April 20\, 2019. Please refer to the application instructions in the Conference Description section below for more details (if available).
URL:https://ces.b2sg.org/event/grs-meeting20jul19/
LOCATION:Holderness School\, 33 Chapel Ln\, Holderness\, NH\, 03245\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/grs_logo_rgb-e1525287092671.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20190610T083000
DTEND;TZID=Europe/Paris:20190610T173000
DTSTAMP:20190406T230809Z
CREATED:20190406T003000Z
LAST-MODIFIED:20190406T230809Z
UID:21178-1560155400-1560187800@ces.b2sg.org
SUMMARY:Royal Society Meeting: Epigenetics
DESCRIPTION:This conference will provide detailed updates in the exciting field of Epigenetics\, focusing on how chemical modifications to our DNA can shape our health from conception to old age from one generation to the next. Epigenetics is emerging as a key player in medicine. \nThe topics discussed will provide an unparalleled opportunity for those wishing to learn more about the fascinating world of epigenetics with an exciting and engaging overview of its past\, present and potential future impact upon our understanding of health and disease. \nCommon unexplained questions such as; how does nature compete with nurture? Why aren’t identical twins actually identical? What elements in our epigenomes affect the health of our children? Can a better understanding of this fascinating field provide those missing parts of the aetiology puzzle? Will be explored and discussed.  \nLeading experts in the field of epigenetic research will present\, discuss\, debate and answer questions on its increasing relevance within a diverse range of clinical disciplines\, as well as sharing their inspirational work that has granted them international renown. \nTopics include: \n\nUnderstanding epigenetics and the role of chemical modifications to DNA in shaping health and disease\nExploring our increasing appreciation of the impact of epigenetics upon a diverse range of biological processes and diseases\, from cancer to mental health\nRecognising the increasing importance of developing an understanding of epigenetics in clinical practice\nDiscussing the role of epigenetics in developmental programming and the bridge between nature and nurture\n\nWhether possessed of an existing clinical or research interest in epigenetics or completely new to the subject\, all are welcome at this event. \nEarly Bird pricing available until 19 April 2019. \n  \nProgramme: \nMelita Irving\, Guy’s and St Thomas’ NHS Foundation Trust: Welcome and introduction \nStephan Beck\, UCL Cancer Institute: Getting up close and personal with epigenetics in health and disease \nSiddharth Banka\, Manchester University NHS Foundation Trust: Histone lysine methyltransferases and demethylases in developmental disorders \nJonathan Mill\, University of Exeter Medical School: Epigenetics and neuropsychiatric phenotypes \nDavid Lehane\, University of Sheffield: Epigenetics and primary care \nNessa Carey\, Imperial College London:  Epigenetics – What are the big questions? \nWolf Reik\, University of Cambridge: Gene regulation in mammalian development \nKaren Lilycrop\, University of Southampton: Epigenetics and development programming \nAzim Surani\, University of Cambridge: Pluripotency and germ cell fate determination \nRobert Brown\, Imperial College London: Epigenetic modification following chemotherapy for ovarian cancer \nSir Adrian Bird\,  University of Edinburgh: Keynote lecture: The genetics & epigenetics of DNA methylation and rett syndrome \nPanel discussion:  \nMelita Irving\, Stephan Beck\, Nessa Carey\, Sir Adrian Bird  \nRebecca Oakey\, King’s College London \nRichard Gibbons\, Oxford University Hospitals NHS Foundation Trust \nAlastair Sutcliffe\, University College London \nIdriss Bennani-Baiti\, Cancer Epigenetics Society \n  \n  \nAdditional information on registration and deadlines may be found at the event’s page.
URL:https://ces.b2sg.org/event/rsm-meeting-10jun19/
LOCATION:Royal Society of Medicine\, 1 Wimpole Street\, London\, W1G 0AE\, United Kingdom
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2019/04/RSM-logo-e1507119214736.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190531
DTEND;VALUE=DATE:20190605
DTSTAMP:20181011T120215Z
CREATED:20181010T220232Z
LAST-MODIFIED:20181011T120215Z
UID:20736-1559260800-1559692799@ces.b2sg.org
SUMMARY:ASCO Annual Meeting
DESCRIPTION:ASCO wants to ensure that you never miss a deadline. From the opening of registration and hotel reservations to the release of abstracts\, keep these dates in mind as you prepare to attend the 2019 ASCO Annual Meeting. \n  \nEARLY FEBRUARY\, 2019\nGroup and Exhibitor Registration Open \nFEBRUARY 12\, 2019 AT 11:59 PM EST\nAbstract submission deadline \nMARCH 14\, 2019 AT 12:00 PM (NOON) EST\nLate-Breaking Data Submission Deadline (authors must submit a shell/placeholder by the February 12\, 2019 deadline to be considered for Late-Breaking Submission) \nAPRIL 24\, 2019\nEarly Registration Deadline
URL:https://ces.b2sg.org/event/asco2019/
LOCATION:McCormick Place\, 2301 S King Dr\, Chicago\, IL\, 60616\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2018/10/ASCO-2019_for_website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190501
DTEND;VALUE=DATE:20190505
DTSTAMP:20190414T134238Z
CREATED:20190414T133535Z
LAST-MODIFIED:20190414T134238Z
UID:21194-1556668800-1557014399@ces.b2sg.org
SUMMARY:Chromatin and Epigenetics
DESCRIPTION:Conference Overview\nEpigenetics refers to heritable change in gene expression that does not involve changes to the underlying DNA sequence. At least three systems including DNA methylation\, histone modifications and non-coding RNAs (ncRNA) are considered to play fundamental roles in epigenetic regulation. Research over the last two decades has uncovered the role of epigenetics in a variety of human disorders and fatal diseases. Moreover influence of age\, environment\, lifestyle\, and disease state on epigenetic states is being increasingly appreciated and actively studied. \nThis conference provides an international forum for cutting edge research in chromatin and epigenetics. It provides the “focal hub” for people to present their research and exchange ideas in a European venue. Renowned speakers will cover the latest advances in the field\, including chromatin regulation\, chromatin dynamics\, signalling to chromatin\, nuclear architecture and dynamics\, developmental epigenetics\, epigenomics\, epigenetics and human diseases\, genome stability\, environmental epigenetics\, and transgenerational inheritance. \nSession Topics\n\nEpigenetic reprogramming\nDevelopmental epigenetics\nDifferent states of chromatin\nHistone modifications\, RNA and metabolism\nTranscriptional and posttranscriptional regulation\nNuclear architecture\nChromatin and its variants in disease\n\nSpeakers: \nAsifa Akhtar\nMax Planck Institute of Immunobiology and Epigenetics\, Germany \nGeneviève Almouzni\nInstitut Curie\, France \nWendy Bickmore\nThe University of Edinburgh\, UK \nAndrea Brand\nThe Gurdon Institute\, University of Cambridge\, UK \nHoward Y. Chang\nStanford University\, USA \nL. Stirling Churchman\nHarvard Medical School\, USA \nIbrahim Cissé\nMassachusetts Institute of Technology\, USA \nXavier Darzacq\nUniversity of California\, Berkeley\, USA \nCaroline Dean\nJohn Innes Centre\, UK \nJoseph R. Ecker\nHHMI & The Salk Institute for Biological Studies\, USA \nEmma Farley\nUniversity of California\, San Diego\, USA \nAnne Ferguson-Smith\nUniversity of Cambridge\, UK \nPolly Fordyce\nStanford University\, USA \nEileen Furlong\nEMBL Heidelberg\, Germany \nEdith Heard\nEMBL Heidelberg\, Germany \nSteven Henikoff\nFred Hutchinson Cancer Research Center\, USA \nGary H. Karpen\nUC Berkeley\, Lawrence Berkeley National Lab\, USA \nJean-Christophe Marine\nVIB-KU Leuven Center for Cancer Biology\, Belgium \nAna Pombo\nMax Delbrück Center for Molecular Medicine\, Germany \nChris Ponting\nThe University of Edinburgh\, UK \nWolf Reik\nBabraham Institute\, UK \nAmos Tanay\nWeizmann Institute of Science\, Israel \nIgor Ulitsky\nWeizmann Institute of Science\, Israel \nFred Winston\nHarvard Medical School\, USA
URL:https://ces.b2sg.org/event/embo-meeting1may19/
LOCATION:EMBL Heidelberg\, Meyerhofstraße 1\, Heidelberg\, 69117 \, Germany
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/EMBO_Logo_grey-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190329
DTEND;VALUE=DATE:20190404
DTSTAMP:20181011T120426Z
CREATED:20181010T185414Z
LAST-MODIFIED:20181011T120426Z
UID:20732-1553817600-1554335999@ces.b2sg.org
SUMMARY:AACR Annual Meeting 2019
DESCRIPTION:Integrative Cancer Science • Global Impact • Individualized Patient Care \nFriday\, March 29-Wednesday\, April 3\, 2019\nGeorgia World Congress Center\nAtlanta\, Georgia \n  \nProgram Committee Chair\nJohn D. Carpten\, USC Keck School of Medicine\, Los Angeles\, California \n\nDownload the Call for Abstracts\nAbstract Submission Deadline: Thursday\, Nov. 15\, 2018\, 11:59 p.m. ET\nLate-Breaking and Clinical Trials Abstract Submission Deadline: Thursday\, Jan. 10\, 2019\, 11:59 p.m. ET\nHousing Deadline: Wednesday\, Feb. 13\, 2019\nEarly Registration Deadline: Friday\, Dec. 7\, 2018\, 11:59 p.m. ET\n\nThe AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology\, translational\, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.  More information about the AACR Annual Meeting 2019 will be available online and in the Call for Abstracts in late August 2018.  \nProgram Committee Vice Chairs\nKenneth C. Anderson\, Dana-Farber Cancer Institute\, Boston\, Massachusetts\nMarcia R. Cruz-Correa\, University of Puerto Rico Comprehensive Cancer Center\, San Juan\, Puerto Rico\nTodd R. Golub\, Broad Institute of MIT and Harvard\, Cambridge\, Massachusetts\nStephen D. Hursting\, University of North Carolina at Chapel Hill\, Chapel Hill\, North Carolina\nPatricia M. LoRusso\, Yale Cancer Center\, New Haven\, Connecticut\nRichard M. Marais\, Cancer Research UK Manchester Institute\, Manchester\, United Kingdom\nAviv Regev\, Massachusetts Institute of Technology and Broad Institute of MIT and Harvard\, Cambridge\, Massachusetts\nAntoni Ribas\, UCLA Medical Center\, Los Angeles\, California\nBrian M. Rivers\, Morehouse School of Medicine\, Atlanta\, Georgia\nDavid A. Tuveson\, Cold Spring Harbor Laboratory Cancer Center\, Cold Spring Harbor\, New York \nProgram Committee Cochairs\nNilofer S. Azad\, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center\, Baltimore\, Maryland\nAnna D. Barker\, Arizona State University\, Scottsdale\, Arizona\nJulian Blagg\, Institute of Cancer Research\, Sutton\, Surrey\, United Kingdom\nJohn M. Carethers\, University of Michigan\, Ann Arbor\, Michigan\nLouis Chesler\, Institute of Cancer Research\, Sutton\, United Kingdom\nDavid C. Christiani\, Harvard Medical School\, Boston\, Massachusetts\nMario P. Colombo\, Fondazione IRCCS Istituto Nazionale Tumori\, Milan\, Italy\nJoseph N. Contessa\, Yale University\, New Haven\, Connecticut\nLisa M. Coussens\, OHSU Knight Cancer Institute\, Portland\, Oregon\nDavid W. Craig\, USC Keck School of Medicine\, Los Angeles\, California\nChristina Curtis\, Stanford University\, Stanford\, California\nRiccardo Dalla-Favera\, Columbia University Institute for Cancer Genetics\, New York\, New York\nCaroline Dive\, Cancer Research UK Manchester Institute\, Manchester\, United Kingdom\nLaura Fejerman\, University of California\, San Francisco\, San Francisco\, California\nKevin L. Gardner\, Columbia University\, New York\, New York\nDavid R. Gius\, Northwestern University\, Chicago\, Illinois\nMithat Gönen\, Memorial Sloan Kettering Cancer Center\, New York\, New York\nJennifer Rubin Grandis\, University of California\, San Francisco\, San Francisco\, California\nJohn D. Groopman\, Johns Hopkins University School of Public Health\, Baltimore\, Maryland\nSusan E. Hankinson\, University of Massachusetts Amherst\, Amherst\, Massachusetts\nJamie N. Holloway\, Georgetown University\, Washington\, District of Columbia\nCatriona H.M. Jamieson\, UCSD Moores Cancer Center\, La Jolla\, California\nPeter Kuhn\, University of Southern California\, Los Angeles\, California\nSherene Loi\, Peter MacCallum Cancer Centre\, Camberwell\, Victoria\, Australia\nThomas J. Lynch\, Jr.\, Bristol-Myers Squibb Co.\, New York\, New York\nCrystal L. Mackall\, Stanford University School of Medicine\, Stanford\, California\nTak W. Mak\, Campbell Family Institute for Breast Cancer Research\, Toronto\, Ontario\, Canada\nHiroyuki Mano\, National Cancer Center Research Institute\, Tokyo\, Japan\nGordon B. Mills\, OHSU Knight Cancer Institute\, Portland\, Oregon\nLisa A. Newman\, Henry Ford Health System\, Detroit\, Michigan\nKunle Odunsi\, Roswell Park Cancer Institute\, Buffalo\, New York\nMoshe Oren\, Weizmann Institute of Science\, Rehovot\, Israel\nKlaus Pantel\, University Medical Center Hamburg\, Hamburg\, Germany\nWilliam Pao\, Roche Pharma Research and Early Development\, Basel\, Switzerland\nLuis F. Parada\, Memorial Sloan Kettering Cancer Center\, New York\, New York\nElectra D. Paskett\, Ohio State University Comprehensive Cancer Center\, Columbus\, Ohio\nEdith A. Perez\, Genentech\, Inc.\, South San Francisco\, California\nEric H. Rubin\, Merck Research Laboratories\, North Wales\, Pennsylvania\nAnil K. Rustgi\, University of Pennsylvania School of Medicine\, Philadelphia\, Pennsylvania\nPatty Spears\, UNC Lineberger Comprehensive Cancer Center\, Chapel Hill\, North Carolina\nVictor E. Velculescu\, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine\, Baltimore\, Maryland\nJennifer A. Wargo\, The University of Texas MD Anderson Cancer Center\, Houston\, Texas\nE. John Wherry III\, University of Pennsylvania\, Philadelphia\, Pennsylvania\nLouis M. Weiner\, Georgetown Lombardi Comprehensive Cancer Center\, Washington\, District of Columbia \n  \nAbout the Location\nAtlanta\, the capital of and the most populous city in Georgia\, is a cultural and economic center of the state and the ninth largest metropolitan area in the United States. The city is the primary transportation hub of the Southeastern United States\, via highway\, railroad\, and air\, with Hartsfield–Jackson Atlanta International Airport being the world’s busiest airport since 1998. Atlanta is home to nationally renowned private colleges and universities\, most notably Emory University\, a leading liberal arts and research institution that ranks among the top 20 schools in the United States. Emory University – home to Winship Cancer Institute – also operates Emory Healthcare\, the largest health care system in Georgia.
URL:https://ces.b2sg.org/event/aacr-29mar19/
LOCATION:Georgia World Congress Center\, 285 Andrew Young International Blvd NW\, Atlanta\, GA\, 30313\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/10/aacr-2019.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190317
DTEND;VALUE=DATE:20190322
DTSTAMP:20180519T220059Z
CREATED:20180519T215918Z
LAST-MODIFIED:20180519T220059Z
UID:20110-1552780800-1553212799@ces.b2sg.org
SUMMARY:Epigenetics and Human Disease
DESCRIPTION:Epigenetics is a major mechanism in human health and disease. Data from a range of diseases (cancer\, neurological and immunological disorders) have uncovered altered epigenomes arising from mutations\, altered expression and/or copy number alterations of numerous epigenetic factors (histones\, DNA and chromatin modifying enzymes\, reader proteins\, chromatin modulators and noncoding RNAs). Genome-wide analyses have illustrated the relationship between altered epigenetic states (e.g.\, modified DNA\, histones and chromatin packaging) and disease onset and progression. Furthermore\, both local and long-range nuclear chromatin architecture are increasingly recognized as major contributors to normal and pathologic epigenetic states.  \nThis meeting\, held jointly with “3D genome”\, will cover the most current knowledge of epigenetic events modulating nuclear function (gene expression regulation\, enhancer modulation\, domains and structural organization as well as cell division and differentiation)\, while relating this to normal and disease models. In addition\, this meeting will highlight the impact that preclinical and clinical epigenetic therapeutics have on multiple diseases including cancer\, immunology\, and neurological disorders. An interdisciplinary panel of speakers including both thought leaders in the field as well as young investigators will survey the latest research results and conceptual understanding of fundamental mechanisms of epigenetic signaling\, especially as relates to regulation of gene expression programs. Presentations and workshops will highlight the latest technologies and methodologies for studying epigenetic states and 3D chromatin architecture in cells\, tissues and organisms. \n  \nThe meeting will begin on Sunday\, March 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday\, March 21 with a closing plenary session from 17:00 to 19:00\, followed by a social hour and entertainment. We recommend return travel on Friday\, March 22 in order to fully experience the meeting.  \n  \nProgram: \n– 3D Epigenome/Epigenetics and Disease \n-Workshop: 4DN Nucleome Consortium Resources \n-Epigenetic Dysregulation in Neurobiology  \n-Single Cell Analysis of Genome Architecture  \n-Understanding and Targeting Epigenetic Dysregulation \n-Analysis of 3D Genome with Advanced Microscopy  \n– Workshop: ENCODE Consortium Resources \n-Infectious Diseases and Autoimmunity  \n-Chromatin and Epigenetics  \n-Chromatin Signaling and Epigenetic Mechanisms \n-3D Genome and Gene Regulation \n-Workshop: International Human Epigenome Consortium  \n-Metabolic Diseases and Aging \n-Genome Architecture and Development \n-Epigenetic Regulation in Immunoncology and Cancer Therapeutics  \n-Computational Analysis of 3D Genome \n-3D Genome and Disease \n  \nDeadlines: \nScholarship Deadline: Nov 15\, 2018 \n Discounted Abstract Deadline: Nov 15\, 2018\n Abstract Deadline: Dec 12\, 2018\n Discounted Registration Deadline: Jan 22\, 2019 \n 
URL:https://ces.b2sg.org/event/keystone-17mar19/
LOCATION:Fairmont Banff Springs\, 405 Spray Avenue\, Banff\, Alberta\, T1L 1J4\, Canada
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/keystone-e1494159273833.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190316
DTEND;VALUE=DATE:20190322
DTSTAMP:20200520T163106Z
CREATED:20181103T154012Z
LAST-MODIFIED:20200520T163106Z
UID:20805-1552694400-1553212799@ces.b2sg.org
SUMMARY:USCAP 108th Annual Meeting: ASCP & ASIP Joint Meeting
DESCRIPTION:Current and Future Revolution in Pathology Practice: (Focus on) Immuno-oncology and Cancer Epigenetics \nASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice\, science\, and challenges of immuno-oncology and cancer epigenetics intended to inform and education residents\, fellows\, and practicing pathologists.  The course will begin with a practical discussion of IO in current practice (Mamatha Chivukula\, Sutter Health\, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc.\, with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions. This will be followed up by a discussion of cutting-edge science in the IO space (Mike Milone\, UPenn) with emphasis on those technologies and tools that are likely to move into clinical space soon. This same approach to cancer epigenetics (David Williams\, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics.  To finish off\, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (I.M. Bennani-Baiti\, President & CEO\, Cancer Epigenetics Society). This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care. \nCourse Learning Objectives\nUpon completion of this educational activity\, the learner will be able to: \n\nReview the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc. with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions\nIdentify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics\nAssess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care\n\n\nSESSION CHAIRS\n\nModerator \nDanny Milner\, MD\, MSc\, ASCP\n\n\n\n\n\nPRESENTATIONS\n\n\n1:30 PM\n1:35 PM\n\n\nIntroduction to the Session and Outline of the Symposium Objectives\n\n\nDanny Milner\, MD\, MSc\nASCP\n\n\n\n\n\n\n\n1:35 PM\n2:10 PM\n\n\n“Immunotherapy” From Bench to Community Practice- Are Pathologists Ready for the #gamechanger?\n\n\nMamatha Chivukula\, MD\, FASCP\nMills-Peninsula Hospital\, Sutter Health Affiliate\n\n\n\n\n\n\n\n2:10 PM\n2:45 PM\n\n\nCutting Edge Science in Immuno-Oncology: Where to next?\n\n\nMichael Milone\, MD\, PhD\nUniversity of Pennsylvania Perelman School of Medicine\n\n\n\n\n\n\n\n2:45 PM\n3:20 PM\n\n\nBreak\n\n\n\n\n\n\n3:20 PM\n3:55 PM\n\n\nFrom DNA Methylation to Chromatin Remodeling\, the Expanding Role of Epigenetic Changes in Cancer Biology\n\n\nDavid Williams\, MD\, PhD\nUniversity of North Carolina at Chapel Hill\n\n\n\n\n\n\n\n3:55 PM\n4:30 PM\n\n\nPractical Epigenetics: How Today’s Cancer Epigenetics Research Will Change the Field of Pathology Tomorrow\n\n\nI.M. Bennani-Baiti\, PhD\, MSc\, FRSM\, CRSM\nCancer Epigenetics Society\n\n\n\n\n\n\n\n4:30 PM\n5:00 PM\n\n\nPanel Discussion\n\n\nDanny Milner\, MD\, MSc
URL:https://ces.b2sg.org/event/events-uscap108/
LOCATION:Gaylord National Harbor Convention Center\, 201 Waterfront Street\, National Harbor\, MD\, 20745\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/11/USCAP.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190224
DTEND;VALUE=DATE:20190301
DTSTAMP:20180518T151309Z
CREATED:20180518T151309Z
LAST-MODIFIED:20180518T151309Z
UID:20101-1550966400-1551398399@ces.b2sg.org
SUMMARY:Long Non-Coding RNAs: From Molecular Mechanism to Functional Genetics
DESCRIPTION:Although emerging evidence point to the critical importance of the long non-coding transcriptome in human physiology and pathology\, the clinical potential of long non-coding RNAs (lncRNAs) as therapeutic and prognostic targets remain largely unexplored. The increasing availability of high throughput technologies and newly developed computational methodologies are rapidly making it possible to address this gap in our knowledge. However\, optimal use of these new capabilities and recognition of their power in transforming the field of lncRNA research require the formation of new collaborative and training efforts. In proposing this meeting\, which is one of the few meetings dedicated to dissemination of novel findings in the lncRNA field\, we specifically aim to: 1) Communicate the latest available technologies and developing methodologies for lncRNA functional genetics to the lncRNA community.  \nWe anticipate that by raising awareness of the ready feasibility of human functional genetic studies\, this meeting will promote collaborations and new research directions that will bridge the already thriving lncRNA mechanistic and basic research to the clinical need for novel\, effective diagnostic\, prognostic and therapeutic targets; 2) By highlighting and promoting the emerging feasibility of performing lncRNA functional genetics\, we hope that the meeting can contribute to attracting the attention of biotech and pharmaceutical industry and clinically-oriented funding agencies to the lncRNA field; and 3) Through holding a joint meeting with the RNA-protein interaction field\, we anticipate the formation of new collaborative efforts that will accelerate the integration of the lncRNA research into the existing body of biological knowledge. \n\nProgram: \n-Functional RNA Elements in Mammalian Genomes \n-lncRNAs\, Transposons and Evolution of the Genome \n-RNP in Phase Transition \n-Coding and Non-Coding RNAs on Chromatin \n-Regulation of Differentiation and Development by lncRNAs  \n-Dissecting RNP Functions in vivo  \n-lncRNAs in Disease: Tools for Discovery  \n-RNA Transport and Localization  \n-Novel Insights into Functional Mechanism of lncRNAs  \n-Structure and Function of RBPs \n-lncRNAs: Diversity in Form and Function  \n-RNP Machines and Regulation  \n-RNA and RBP in Disease \n  \n  \nDEADLINES:\n*All deadlines end at 11:59 PM US Mountain Standard Time\nScholarship Deadline: Oct 25\, 2018\nDiscounted Abstract Deadline: Oct 25\, 2018 \nAbstract Deadline: Nov 29\, 2018 \nDiscounted Registration Deadline: Jan 10\, 2019 
URL:https://ces.b2sg.org/event/keystone1-24feb19/
LOCATION:Whistler Conference Centre\, 4010 Whistler Way\, Whistler\, V0N 1B4\, Canada
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/keystone-e1494159273833.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181201
DTEND;VALUE=DATE:20181205
DTSTAMP:20180517T141436Z
CREATED:20180517T141436Z
LAST-MODIFIED:20180517T141436Z
UID:20095-1543622400-1543967999@ces.b2sg.org
SUMMARY:ASH Annual Meeting
DESCRIPTION:The premier event in malignant and non-malignant hematology\nMark your calendar for the world’s most comprehensive hematology event of the year\, the 60th ASH Annual Meeting and Exposition in sunny San Diego. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25\,000 hematology professionals from every subspecialty. \n\nThe ASH annual meeting is made up of numerous sessions\, which fall under the categories below. \nSchedule-at-a-Glance\nA listing of all ASH annual meeting sessions\, events\, and activities organized by time and day \nGeneral Sessions\nSignature sessions designed to be of interest to a broad and diverse audience; they include the Ham-Wasserman Lecture\, announcement of Honorific Award recipients\, the Plenary Scientific Session\, and more \nEducation Program\nSessions from the ASH Education Program \n\nEducation Spotlight Sessions\nSessions that facilitate discussions of evidence-based practice\, decision making\, and controversies in diagnosis and management\nHow I Treat: Bringing Science to Clinical Dilemmas\nSessions designed to provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction\n\nSpecial-Interest Sessions\nSessions on specific topics ranging from best practices for publishing one’s work in a peer-reviewed journal\, to improving practice through quality measures\, to advocating for increased research funding for the National Institutes of Health \n\nConsultative Hematology Course\nAn interactive\, half-day program covering commonly encountered clinical problems that arise in everyday practice and require the expertise of a hematologist\nPolicy and Practice Events\nPolicy and practice-related events held during the annual meeting\n\nScientific Program\nSessions from the ASH Scientific Program \n\nContinuing Conversations With the Speakers\nInformal discussions with Scientific Program session speakers designed to give interested individuals increased accessibility both to information on the topic and to the opinions of experts in those particular fields\nFriday Scientific Workshops\nTopic-specific workshops presented on the Friday prior to the annual meeting featuring presentations by world-class scientists\, as well as young and mid-level principal investigators\nMeet the Scientist\nSessions designed to provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction\nScientific Spotlight Sessions\nSessions covering current challenges and controversies in a particular scientific field\nSpecial Scientific Symposia\nSymposia highlighting transformative research with implications for research and clinical practice across the field of hematology\n\nTrainee Activities and Services\nActivities and services relevant to the unique interests of undergraduates\, medical and graduate students\, residents\, and fellows \n\nKey Dates\n\n\n\nAbstract submission site opens\nMay 31\, 2018\n\n\nASH Foundation Run/Walk registration opens\nJuly 5\, 2018\, 11:00 a.m. Eastern time\n\n\nMember-only registration and housing opens\nJuly 18\, 2018\, 11:00 a.m. Eastern time\n\n\nAdvance registration and housing opens for non-members\nAugust 8\, 2018\, 11:00 a.m. Eastern time
URL:https://ces.b2sg.org/event/ash-1dec18/
LOCATION:San Diego Convention Center\, 111 W Harbor Dr\, San Diego\, CA\, 92101\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/american_society_of_hematology-ash.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181127
DTEND;VALUE=DATE:20181201
DTSTAMP:20180515T150529Z
CREATED:20180515T150201Z
LAST-MODIFIED:20180515T150529Z
UID:20073-1543276800-1543622399@ces.b2sg.org
SUMMARY:Systems Epigenetics: Towards Precision Cancer
DESCRIPTION:This conference brings together scientists from multidisciplinary fields employing different research strategies: (1) Epigenetic profiling at genome-wide and/or single cell level to identify complex dynamic regulatory interactions\, (2) Bioinformatics and mathematical modelling to understand and predict observed (dynamic) phenotypic responses\, (3) Innovative epigenetic interference tools using for instance CRISPR/dCas-based epigenetic editing tools to locally overwrite epigenetic signatures and to verify the impact of defined alterations in epigenetic regulation. The meeting provides a platform for scientists focusing on fundamental and biomedical research\, clinicians and private sector scientists. \nProgram: \nEpigenetic regulatory mechanisms: ‘State-of-the-art epigenetics’  \nEpigenetics and clinical cancer: A systems medicine view  \nEpigenetics and clinical cancer: metabolic reprogramming  \nInnovative epigenetic interference tools and synthetic biology \nEpigenetics\, cell heterogeneity and cancer stem cells driving tumour evolution \n 
URL:https://ces.b2sg.org/event/epipredict-27nov18/
LOCATION:KIT – Royal Tropical Institute\, Mauritskade 63\, Amsterdam\, 1092\, Netherlands
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/epipredict-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181106
DTEND;VALUE=DATE:20181111
DTSTAMP:20180915T013356Z
CREATED:20180915T000152Z
LAST-MODIFIED:20180915T013356Z
UID:20630-1541462400-1541894399@ces.b2sg.org
SUMMARY:EpiCypher 2018
DESCRIPTION:Overview \nThis exciting four-day conference at the beautiful luxury oceanfront Meliá Nassau Beach all inclusive resort in Nassau\, Bahamas will highlight recent breakthroughs in epigenetics and chromatin research and will foster the collaboration and exchange of scientific expertise and knowledge in one of the most vibrant areas of life sciences. Through scientific presentations\, a wide spectrum of topics in epigenetics and chromatin biology will be explored. \nREGISTER NOW \nEpiCypher2018: Biological and Clinical Frontiers in Epigenetics will feature keynote addresses by Dr. C. David Allis and Dr. Kristian Helin. Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Dr. Helin is a Professor at the University of Copenhagen and the director of the Danish National Research Foundation’s Centre for Epigenetics. \nThe plenary session talks will cover broad aspects of epigenetics and chromatin biology\, ranging from basic molecular mechanisms to therapeutic efforts. There will be discussions around the elucidation of novel mechanisms\, new tools\, and other breaking topics in epigenetics and chromatin research. \nREGISTRATION & PRICING – SPACE IS LIMITED FOR THIS MEETING    \nEarly Registration Deadline: October 1\, 2018 \nAbstract Submission Deadline: October 1\, 2018 \nThe meeting is being held and the luxury all-inclusive Meliá Bahams Resort so\, in addition to four nights lodging\, all meals\, and conference materials\, attendees will have access to all amenities the property offers\, including: \n– a special cocktail reception – 24 hour room service (including drinks) – Unlimited dining* – All drinks at the multiple on-site bars and the in-room mini-bar \n*- at the Black Angus steakhouse and Starbucks on-site\, additional charges will apply see full details for “All Inclusive Plan” here – LINK \nAcademic Pricing – Double Occupancy  Early – $1\,450 / Late – $1\,495    \nAcademic Pricing – Single Occupancy  Early – $1\,995 / Late – $2\,095    \nIndustry Pricing – Single Occupancy   Early – $2\,295 / Late – $2\,395 \nGuest Fee*   Early – $295 / Late – $395 \nREGISTER NOW  \nCo-Organizers \nMark Bedford\, Univ. Texas MD Anderson Cancer Center \nOr Gozani\, Stanford University \nDan Levy\, Ben-Gurion University \nBrian Strahl\, University of North Carolina \nThe meeting will begin at 6 PM on Tuesday\, November 6th and Conclude at noon on Saturday\, November 10th \nDownload conference flyer (pdf) \n \n* Guests receive accommodation for the duration of the conference and all-inclusive plan benefits. Maximum 1 adult guest per paid conference attendee. Maximum room occupancy 2 adults and 2 children. Children over 12 are billed at adult guest fee rate. Children under 2 are free. \n  \n  \nSTUDENT TRAVEL AWARDS: \nSeveral Student and Post-doc Travel Awards are available for US/Canada attendees ($500) and for International participants ($750). \nTravel Award Application Deadline: October 1\, 2018 \nTravel Award Notification: October 15\, 2018 \nWho is eligible? These awards are eligible to full-time graduate students that have registered to attend EpiCypher 2018. \nShould I register for the meeting? To attend the meeting\, it will be necessary for you to register. After you register and pay for the meeting\, you may apply for the travel award. \nWhen will I be reimbursed? At the conclusion of the meeting you will need to submit your receipts\, after which we will send you a check for the total amount of your travel expenses or the allotted award amount\, whichever is less. \nHow do I apply for the award?  \nTo apply\, send an email to epicypher2018@epicypher.com with the subject line “EpiCypher 2018 Travel Award Application” and include the following information: 1. Your name 2. Your institution and department 3. The name of your primary investigator / graduate advisor 4. A brief statement describing your research (a single paragraph will suffice)
URL:https://ces.b2sg.org/event/epicypher2018/
LOCATION:Meliá Nassau Beach\, 1 West Bay Street\, New Providence\, Bahamas
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/09/Epicypher-e1536951072492.jpg
ORGANIZER;CN="Mark Bedford":MAILTO:epicypher2018@epicypher.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181105
DTEND;VALUE=DATE:20181108
DTSTAMP:20180515T155251Z
CREATED:20180515T154441Z
LAST-MODIFIED:20180515T155251Z
UID:20079-1541376000-1541635199@ces.b2sg.org
SUMMARY:Making it Personal: Cancer Precision Medicine
DESCRIPTION:After two highly-rated previous editions\, the 3rd EACR conference on the topic of personalised medicine will update you on the latest challenges and advances in targeted and immunological cancer therapies. It will cover a broad spectrum of basic\, translational and clinical research\, all related to currently pressing questions relevant across cancer types. \nThe multidisciplinary programme will encompass developments in diagnosis and early detection\, including novel bioinformatic approaches. New immuno-oncology treatments will also be presented\, emphasising the role of the tumour microenvironment and showcasing systems immunology. The emergence and role of drug-tolerant tumour fractions will be discussed in the context of drug resistance. And\, reflecting one of the major needs\, there will be a focus on rational design of combinatorial therapies and on how advances emerging from the laboratory are clinically implemented. \nThe programme includes 17 plenary lectures\, dedicated poster sessions and interactive elements. The small size of the conference makes it an excellent forum to share new data\, and to network with colleagues and speakers. \nWho should attend?\nWe welcome all basic\, translational and clinical scientists (including postdocs and trainees)\, who are interested in tackling pressing cancer-relevant questions\, and who want to hear the latest developments in therapies targeting cancer and immune cells. We also invite industry scientists who are interested in targets for novel therapies. This is an excellent forum for informal networking and meeting potential collaborators. \nTopics to be covered\n\nDiagnosis\nEarly detection\nTumour microenvironment\nImmuno-oncology\nTargeted tumour therapy\nDrug tolerance\nComputational discovery of cancer vulnerabilities\nTherapy resistance\nClonal evolution\nRational treatment combinations\nClinical implementation of exceptional responder data\n\n  \nKey dates\nBursary application deadline:\n03 September 2018 \nAbstract submission deadline:\n03 September 2018 \nRegistration deadline:\n01 October 2018
URL:https://ces.b2sg.org/event/eacr-5nov18/
LOCATION:Centro Congressi Giovanni XXIII\, Viale Papa Giovanni XXIII\, Bergamo\, 24121\, Italy
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/EACR-new-logo-jpeg-e1526380502516.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181014
DTEND;VALUE=DATE:20181018
DTSTAMP:20180513T140011Z
CREATED:20180512T233157Z
LAST-MODIFIED:20180513T140011Z
UID:20060-1539475200-1539820799@ces.b2sg.org
SUMMARY:From epigenome towards epitranscriptome in cell fate choice
DESCRIPTION:About the Workshop\n\nIn the central dogma of molecular biology\, RNA was thought only to pass genetic information from DNA to protein. Most recent findings strongly indicate that RNA modifications\, like mRNA methylation\, play dynamic regulatory roles that are analogous to the reversible epigenetic modifications of DNA and histone proteins. Understanding the function and mechanisms of the dynamic RNA modifications\, which are termed ‘RNA epigenetics’\, represents a new challenge at the frontier between different disciplines\, such as biochemistry\, epigenetics and cutting-edge technology. \nReversible RNA modifications add a new dimension to the developing picture of post-transcriptional regulation of gene expression. This new dimension awaits integration with transcriptional regulation\, i.e. DNA modifications\, to decipher the multi-layered information that controls a plethora of biological functions. Thus\, in the era of advanced technologies\, the exciting next step is to move from mapping nucleotide modifications to understanding how they contribute to biological processes. \nThis EMBO Workshop involves sessions dedicated to recent advances in the epigenomic and epitranscriptomic regulation of stem cell pluripotency and differentiation\, organismal development\, and how their alteration brings about human diseases. Particular emphasis on approaches enabling targeted manipulation of epigenetic marks\, which are revolutionising the field\, will be addressed. \nTopics to be covered include: \n1. Dynamic DNA and RNA modifications: Writers\, erasers\, and readers. This session will be dedicated to the discovery and functional elucidation of the enzymes dynamically modifying and demodifying DNA and RNA molecules. Also\, progress made on identification and characterization of proteins mediating the effects of these modifications into biological function will be discussed. \n2. Decoding the function of DNA and RNA modifications: Insights from epigenome editing and other approaches. The second session will provide new insights on the emerging approaches useful for an enhanced and more accurate interpretation of DNA and RNA dynamics. For instance\, the targeted deposition or removal of chromatin modifications promises to be a powerful tool in basic research\, to study gene function and chromatin biology\, and also in molecular medicine. \n3. DNA and RNA Epigenetics in Stem Cell and Development. This session will discuss the latest advances on the epi-control of the mechanisms underlying the cell fate decision and early developmental processes\, with a special focus on the embryonic and adult stem cells. Moreover\, DNA and RNA methylation will be discussed in the context of reprogramming events in the developing mouse germ line and zygote. \n4. Epigenomes and Epitranscriptomes: A gateway to understanding diseases. In this session\, the discussion will be focused on how understanding the regulation of DNA and RNA modifications paves the way towards identifying causes and cures for human diseases\, with particular emphasis on cancer\, muscle diseases and autoimmune disorders. \n\nRegistration\n\nABSTRACT SUBMISSION: 01 April 2018 – 15 June 2018 \nCHOSEN PARTICIPANTS WILL BE NOTIFIED BY 30 June 2018 \nTRAVEL GRANT APPLICATION: 01 April – 15 June 2018 \nREGISTRATION DEADLINE: 31 July 2018
URL:https://ces.b2sg.org/event/embo-14oct18/
LOCATION:Hotel La Palma\, Capri\, Italy
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/EMBO_Logo_grey-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181009
DTEND;VALUE=DATE:20181013
DTSTAMP:20180512T125811Z
CREATED:20180512T125332Z
LAST-MODIFIED:20180512T125811Z
UID:20046-1539043200-1539388799@ces.b2sg.org
SUMMARY:3rd Danube Conference on Epigenetics
DESCRIPTION:The main objectives are to bring scientists together from the fields of epigenetics and promote intensive interdisciplinary interactions facilitated by the medium sized meeting. Therefore the conference program is structured to have a lot of networking opportunity. We expect to have 150 participants including 20 outstanding invited lecturers (please find here the list of confirmed speakers including the IUBMB Keynote speaker). We also plan to select several short talks from the submitted abstracts.\nI sincerely hope that you will find this invitation interesting and will decide to participate.\nYours truly\,\nTamás Arányi\, MD\, PhD On behalf of the organizing committee#\n\n\n\n\n\n\n\nCall for Abstracts\nAbstracts are awaited in the following topics: \n\nDNA methylation\nChromatin structure\nDevelopmental epigenetics\nTranscription and epigenetics\nMetabolism and epigenetics\nnon-coding RNA\n\nAbstracts are also welcome for all other areas of epigenetics as in the previous years. \nThe abstracts should be prepared according to the following guidelines: \n\nTitle of abstract\nFull name of author(s)\, (Please write the full name for all co-authors\, do not use initials)\nAffiliation of author(s)\, (Working place\, City\, Country\, e-mail address)\nIn case of multiple authors / affiliations\, please use index numbers in superscript\nLength of abstract: max 250 words\nMS Word file\, Times New Roman font type\, 12 pts font size\, single line spacing required\nText files should not contain headers or footers\nPlease avoid abbreviations\, if used\, please elaborate it at the first time 
URL:https://ces.b2sg.org/event/febs-9oct18/
LOCATION:Hungarian Academy of Sciences\, Magyar tudósok körútja 2\, Budapest\, 1117\, Hungary
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/febs-final.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181004
DTEND;VALUE=DATE:20181007
DTSTAMP:20180510T224127Z
CREATED:20180510T224048Z
LAST-MODIFIED:20180510T224127Z
UID:20037-1538611200-1538870399@ces.b2sg.org
SUMMARY:2nd Epigenetics and Bioengineering Conference
DESCRIPTION:Advancing our Interfaces with the Epigenome \nPresented by the Society for Biological Engineering (SBE)\, EpiBio 2018 is a forum for engineers and scientists who are applying the tools and techniques of bioengineering to the area of epigenetics. Academic\, clinical\, and industrial researchers from several disciplines are invited to share their recent discoveries and developments\, and the overarching goal of the conference is to shape the future of this emerging field. \nCall for Abstracts is now open until July 6th\, 2018\n\nThe body of fundamental knowledge related to epigenetic modifications of proteins and nucleic acids as well as the mechanisms of epigenetic regulation in organisms ranging from microbes to humans is vast and rapidly expanding. Efforts to translate this knowledge into products and processes that benefit society have rapidly followed this explosion in fundamental understanding of molecular biology. \nThese products and processes include new medical diagnostics\, new ways to treat disease\, and enhanced methods of producing therapeutic compounds\, proteins\, and other lucrative chemical products. EpiBio 2018 explores how to advance interfaces with the epigenome\, providing a platform to communicate\, share technical knowledge\, nucleate collaborations and partnerships\, and hear a diverse set of perspectives related to needs\, opportunities and priorities at the intersection of bioengineering and epigenetics. \nSessions:\n\nSensing Epigenetic Modifications\nWriting Epigenetic Modifications\nNuclear Organization\nEpigenetic Diagnostics and Therapeutics\nSingle Cell Epigenetics\nThe Epitranscriptome\nComputation and Modelling in Epigenetics
URL:https://ces.b2sg.org/event/sbe-4oct18/
LOCATION:The Mission Bay Conference Center\, 1675 Owens Street\, San Francisco\, CA\, 94143-3008\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/sbe-society-for-biol-engin.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181003
DTEND;VALUE=DATE:20181007
DTSTAMP:20180505T163255Z
CREATED:20180505T141902Z
LAST-MODIFIED:20180505T163255Z
UID:20017-1538524800-1538870399@ces.b2sg.org
SUMMARY:The Complex Life of RNA
DESCRIPTION:Before the genetic information stored in DNA can be used to direct cell growth and metabolism\, it has to be transferred into RNA.  Messenger RNAs (mRNAs) that code for  proteins and noncoding RNAs are key components in the transmission of genetic information in all life forms – from viruses to complex mammalian organisms. Exciting recent findings now reveal a new layer of information added to RNAs in the form of chemical marks (the epitranscriptome) that play a critical role in gene expression control. This remarkable complexity in the lives of RNAs will be discussed at this meeting. \nThe EMBO | EMBL Symposium “The Complex Life of RNA” will bring leaders in the RNA field together with post-docs and students\, to disseminate and discuss the most recent results. \nSession Topics\n\nTranscription\nRNA processing\nExport and localisation\nmRNA surveillance and decay\nTranslation and the control of mRNA expression by microRNAs\nRNA modifications\nNoncoding RNAs\n\nAbstract submission\nOnly registered participants are eligible to submit an abstract. We only accept online abstract submissions. \nAfter you have logged in and successfully registered\, you will receive an email asking you to submit your abstract.  Click on the link provided and enter your abstract in the text box provided. Alternatively you can submit your abstract by clicking on the link on the confirmation page directly after registering. \nWhen submitting your abstract you can also apply for an oral or poster presentation. A selection process will take place with the results announced 2-3 weeks after the abstract submission deadline. \nPlease check our FAQs pages for further information on how to submit an abstract.
URL:https://ces.b2sg.org/event/embl-3oct18/
LOCATION:EMBL Heidelberg\, Meyerhofstraße 1\, Heidelberg\, 69117 \, Germany
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/EMBL-logo--e1525286945880.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181001
DTEND;VALUE=DATE:20181005
DTSTAMP:20180516T143204Z
CREATED:20180516T142518Z
LAST-MODIFIED:20180516T143204Z
UID:20085-1538352000-1538697599@ces.b2sg.org
SUMMARY:World Cancer Congress
DESCRIPTION:2018 WORLD CANCER CONGRESS\nHosted by the National Cancer Society of Malaysia\, the 2018 Congress will take place from 1-4 October in the Kuala Lumpur Convention Centre (KLCC). \nAccess the full programme\, registration and hotels. \n\n\nInvest in yourself to increase your skill set and foster change – take action now: \n– enrol on a Master Course(link is external) to acquire unique specialised knowledge over three months of distance learning that culminates in a workshop day at the Congress. 95% of past participants said they learnt new tools applicable to their real-world settings. You can choose among the following 2018 topics: \n\nStrengthening capacities of patient groups across the health system\nBuilding cancer awareness and prevention programmes\nUsing the law and policymaking for cancer prevention and control\nCreating fit-for-partnering organisations\n\n– mark your calendar with our social events(link is external) which are useful platforms to network and catch up with colleagues and friends \n– discover top notch plenary speakers(link is external) and meet them in person at the Meet’in Café \n– engage with leading advocates and patient support groups in the Patient Group Pavilion(link is external) \n– secure a stand in the Global Village(link is external) – the heart of the Congress – and shine a light on your initiatives and activities. \nPlease note: registration for Master Courses and social events are made through the official 2018 Congress registration system(link is external). \n\n  \n\nAbout the World Cancer Congress – A major event in the global cancer control agenda\nThe World Cancer Congress (WCC) is a recognised international conference that encourages effective knowledge transfer and best practices exchange amongst + 3000 global cancer control and health experts. \nIt was awarded ‘Best Conference Development’ at the 2016 International & European Associations Awards(link is external) and ‘Best use of social media’ with the 2016 WCC campaign at the 2017 Association Excellence Awards(link is external). \nThe event aims to strengthen the action and impact of the cancer community on national\, regional and international scales through its educational programme which spans the full spectrum of cancer – from prevention and treatment to palliative care. \nThe first International Cancer Congress was held in Madrid in 1933. It led to the foundation of the International Union Against Cancer in 1935\, renamed the Union for International Cancer Control (UICC) in 2010 and today’s proud winner of the International & European Association Award for Membership Engagement. \nThe WCC supports UICC‘s purpose statement ‘to unite the cancer community\, reduce the global cancer burden\, promote greater equity and integrate cancer into the world’s health and development agenda‘. \nThe event takes place every two years in a different country and is hosted by a local member of UICC.
URL:https://ces.b2sg.org/event/uicc2018-1oct18/
LOCATION:UICC World Cancer Congress 2018\, Kuala Lumpur\, Malaysia
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2017/06/UICC_MASTER_BYLINE_RGB-e1526462353637.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180916
DTEND;VALUE=DATE:20180922
DTSTAMP:20180503T173424Z
CREATED:20180502T233132Z
LAST-MODIFIED:20180503T173424Z
UID:19979-1537056000-1537574399@ces.b2sg.org
SUMMARY:Transcription\, Chromatin and Epigenetics
DESCRIPTION:This FASEB SRC is designed to highlight the major advances in science and integrate different topics\, which are part of an extremely fast-moving and exciting field of research. The biological scope and the mechanisms of action of DNA and RNA molecules\, which have roles in dosage compensation\, imprinting\, enhancer function and transcriptional regulation\, have a great impact in health and diseases\, including aging and cancer.\nA key reason for the increasing interest in chromatin and transcription is the appreciation that regulation of chromatin organization and transcription is the fundamental cornerstone for establishing gene expression patterns that determine cell state and fate.  Researchers studying embryonic stem cells\, organism development\, diseases (e.g. cancer) have discovered a common interest in elucidating the mechanisms that govern gene expression. Moreover\, there has been a recent explosion of activity in the fields of RNA epigenetics and non-coding RNAs\, which have become integral parts of the field of gene expression. This five-day conference will gather confirmed and junior scientists from academia\, biotech\, pharma and clinical settings to share ideas and concepts\, and create synergy in the following domains: \n\ntranscription and chromatin in gene regulation\,\nchromatin complexes\,\nDNA and RNA modifications\,\nnon-coding RNAs\,\nstem cells\, aging and cancer.\n\nAs epigenomic is the emerging tool for studying complex diseases\, this conference will highlight the latest technologies and methodologies for studying biological modifications in cells\, tissues and organisms and should attract a lot of attention. Indeed\, researchers nowadays work on comprehensive\, genome-wide datasets across multiple domains and need to be supported by sophisticated technologies. Experts from academia and industry will present their most recent technological developments in different areas of research. This SRC will also highlight “epitranscriptomics” and should attract a whole range of researchers curious to learn the latest advances in this booming area of epigenetics. Scientists using diverse approaches such as molecular biology\, cell biology genetics\, epigenomics\, and biochemistry will come together to discuss their state-of-the-art discoveries. This SRC series has historically brought together scientists involved with diverse systems and strategies\, resulting in exciting and synergistic discussions. 2018 will continue to fulfill this role as a forum for the most advanced science in transcription\, chromatin and epigenetics. Together with junior and leader speakers\, additional oral presentations will be selected from submitted abstracts and there will be opportunity for dynamic and interactive evening poster presentations. Social and recreational activities will provide all registrants an opportunity to mix with senior scientists.  Vibrant interactions between established and young investigators at Meet-the-expert sessions\, poster sessions\, meals\, and social activities provide an ideal opportunity for attendees to meet\, discuss\, and develop new collaborations. \nImportant Deadlines: \n\nEarly bird registration deadline July 23\, 2018\nLast day to register August 2\, 2018\n\nHighlights\n\nWorkshop topics: Career in academia\, career in industry\, grant writing and publication process talks given by experts\nRound table discussions with Experts; poster sessions with light refreshments; social activities\nCompany presentations: latest technologies/product development/new areas of interest/published papers\n\nKeynote Speaker\nDanny Reinberg\nNYU School of Medicine \nConference Organizers\nFrançois Fuks\nUniversity of Brussels\, Belgium\nffuks@ulb.ac.be \nAnne Brunet\nStanford University\nanne.brunet@stanford.edu \nFASEB Conference Staff\nRobin Crawford\, CMP\, Conference Manager \nContact us\nEmail: src@faseb.org\nPhone: 1.301.634.7010 \n 
URL:https://ces.b2sg.org/event/faseb-16sept18/
LOCATION:Hilton Metropole Florence\, Via del Cavallaccio 36\, Florence\, 50142\, Italy
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/FASEB-logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180911
DTEND;VALUE=DATE:20180916
DTSTAMP:20180503T174036Z
CREATED:20180503T000633Z
LAST-MODIFIED:20180503T174036Z
UID:19991-1536624000-1537055999@ces.b2sg.org
SUMMARY:Epigenetics & Chromatin
DESCRIPTION:You are cordially invited to participate in the fourth Cold Spring Harbor Laboratory meeting on Epigenetics & Chromatin. The opening session will begin at 7:30 pm on Tuesday\, September 11 and the meeting will end after lunch on Saturday\, September 15\, 2018. As currently planned\, the program will have eight sessions devoted to oral presentations\, together with three poster sessions for presentations which cannot be accommodated in the formal sessions. Selection of talks for the oral sessions will be made by the organizers in conjunction with the session chairpersons\, from the submitted abstracts. \nKeynote Speakers:\nWendy Bickmore\, MRC Human Genetics Unit\nGerald Crabtree\, Stanford University\n\nTopics:\n\n\nGerm Cell\nDevelopment & Early Development\nEpigenetic Memory\nChanges in Epigenetic State\nGenomic Architecture\nMetabolic Epigenetics\nTechnology: Single Cell & Sculpting the Epigenome\nGene Regulation / Enhancers\n\nAbstracts should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. Status (talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers. \nWe hope that you or a member of your laboratory will be able to participate. In addition\, please bring this announcement to the attention of any other interested parties. We look forward to seeing you at Cold Spring Harbor in September. \nAll questions pertaining to registration\, fees\, housing\, meals\, transportation\, visas\, abstract submission or any other matters should be directed to Val Pakaluk. \nPricing:\n\nAcademic Package $1485\nGraduate/PhD Student Package $1235\nCorporate Package $1905\nAcademic/Student No-Housing Package $1005\nCorporate No-Housing Package $1280
URL:https://ces.b2sg.org/event/csh-11sept18/
LOCATION:Grace Auditorium\, 1 Bungtown Road\, NY\, 11724\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/csh-cold-spring-harbor.jpg
ORGANIZER;CN="Val Pakaluk":MAILTO:pakaluk@cshl.edu
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180825
DTEND;VALUE=DATE:20180829
DTSTAMP:20180503T175527Z
CREATED:20180502T234356Z
LAST-MODIFIED:20180503T175527Z
UID:19985-1535155200-1535500799@ces.b2sg.org
SUMMARY:Transcription and Chromatin
DESCRIPTION:The EMBL Transcription and Chromatin meeting has a long-standing tradition in shaping the field of transcriptional regulation. The meeting brings together leading experts covering all aspects of transcription from cis-regulatory function\, long range regulation\, 3-dimensional looping\, the basal transcriptional machinery\, RNA polymerase regulation and function\, nucleosome positioning\, chromatin modifications\, chromatin remodeling\, and epigenetic inheritance of transcriptional silencing. The meeting contains many talks selected from the abstracts that are interspersed with invited speakers\, discussing the latest breakthroughs in transcriptional regulation. \nThe conference is designed to promote interactive discussions at both the talks and poster sessions. Given the excellent line up of speakers and the meeting’s outstanding reputation\, this is a ‘must’ attend for anyone interested in cutting edge research in transcription. \nSession Topics\n\nActivators\, enhancer function\, evolution and modelling\nLong range transcriptional regulation and enhancers\nGeneral basal transcriptional machinery\nPol II function\, pausing and the role of RNA in transcription\nChromatin modifications and transcription\nTranscriptional regulation during cell fate decisions – stem cell reprogramming and normal embryonic development\nGenome topology and three-dimensional regulation\nSingle cell quantification \n\nDEADLINES: \nRegistration – 16 Jul 2018 \nAbstract – 27 Jun 2018
URL:https://ces.b2sg.org/event/embl-25aug18/
LOCATION:EMBL Heidelberg\, Meyerhofstraße 1\, Heidelberg\, 69117 \, Germany
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/EMBL-logo--e1525286945880.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180722
DTEND;VALUE=DATE:20180728
DTSTAMP:20180507T193523Z
CREATED:20180502T143150Z
LAST-MODIFIED:20180507T193523Z
UID:19965-1532217600-1532735999@ces.b2sg.org
SUMMARY:Chromatin Encounters: Shaping Genome Architecture and Function
DESCRIPTION:The 2018 Gordon Conference on Chromatin Structure and Function will bring together leading experts and newcomers to the field\, to present and discuss their newest research on chromatin\, its complex interactions\, and its regulatory power in shaping genome architecture and function. Technologies to visualize and map chromatin at all levels are proceeding at a rapid pace. The meeting will highlight how chromatin structures\, ranging from the nucleosome – the “building block” of chromatin – up to the dynamic three-dimensional spatial organization of the chromosome\, are assembled\, maintained\, and altered\, and how this ultimately controls genome functions. \nInterconnected questions at the frontier of the field will be addressed – how does the nucleosome interact with other nuclear factors\, how is chromatin assembled\, disassembled\, and maintained in a dynamic state\, what is the molecular basis for the crosstalk between epigenetic modifications and metabolism\, and how does dysfunction of any of these processes result in disease. \nPresentations will encompass a wide variety of innovative technical approaches – from Angstrom level description of chromatin components at all organizational levels to the visualization of micron-scale structures by light microscopy\, and the mapping of chromatin states genome-wide at unprecedented resolution. There will be a focus on new methods to determine chromatin dynamics and the relationships between chromatin structure and function\, and on adapting these to the level of single molecules and single cells. \nApplications for this meeting must be submitted by June 24\, 2018. Please apply early\, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed\, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the conference chair if more seats become available due to cancellations. \nDiversity funding: \nFinancial assistance is available for qualified applicants through the GRC Carl Storm Underrepresented Minority Fellowship Program. This program provides a grant to underrepresented minority graduate students\, postdocs\, faculty and scientists to help fund their attendance at their first GRC meeting.  Learn more.
URL:https://ces.b2sg.org/event/grc-22jul18/
LOCATION:Grand Summit Hotel at Sunday River\, 97 Summit Road\, Newry\, ME\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/GRC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180721
DTEND;VALUE=DATE:20180723
DTSTAMP:20180505T183814Z
CREATED:20180502T231455Z
LAST-MODIFIED:20180505T183814Z
UID:19975-1532131200-1532303999@ces.b2sg.org
SUMMARY:Chromatin: Plasticity and Genome Regulation in Physiology and Disease
DESCRIPTION:The Gordon Research Seminar on Chromatin Structure and Function is a unique forum for graduate students\, post-docs\, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas. \nThe inaugural 2018 Gordon Research Seminar in Chromatin Structure and Function is a meeting for young scientists and established investigators presenting leading-edge research and innovative ideas. The meeting will explore the various aspects of chromatin biology including the hierarchies of chromatin structure\, visualization and engineering of chromatin\, regulation of genome functions and connections between epigenetic modifications and cellular metabolism in the context of development and human disease. A wide range of approaches including genome-wide chromatinomics\, structural biology\, proteomics\, computational modeling and high resolution microscopy will be highlighted in the seminar. \nThe main goal of the Chromatin Structure and Function GRS is to provide unique opportunities for younger attendees to scientifically interact with their peers as well as with established investigators in the field. Following the historic footsteps of the associated GRC\, the Chromatin Structure and Function GRS fosters the exchange of novel ideas\, diverse interactions and long-lasting collaborations. Early-stage scientists will have the opportunity to present their work and obtain feedback from colleagues and experienced scientists\, enabling them to build on their work and potentially explore novel ideas. In addition\, there will be a session dedicated to career advising for graduate students as well as postdocs. Attendees will have a chance to hear about the experiences of scientists at various career stages and explore additional opportunities for professional development. We aim to make the GRS a long-lasting component of the Chromatin Structure and Function GRC and to attract enthusiastic and talented young researchers with eagerness to expand their scientific inquiry. We expect the scientific interactions at the GRS to carry over to the main conference to make it an even more enriching experience for all attendees. \nApplication Instructions\nThe seminar will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS\, either by giving an oral presentation or presenting a poster. Therefore\, all applications must include an abstract. \nThe seminar chair will select speakers from abstracts submitted by April 21\, 2018. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate\, you must submit an application by the date indicated in the Application Information section above. \nProgram Format\nGordon Research Seminars are 2-day meetings which take place on the Saturday and Sunday just prior to the start of the associated GRC. The GRS opens with a 1-hour introductory session on Saturday afternoon\, followed by a poster session\, dinner and a 2-hour session in the evening. Sunday morning begins with breakfast and is followed by another 2-hour session\, a second poster session\, and lunch. A final 1-hour session takes place just after lunch\, and the associated GRC begins later that evening. \nApplications for this meeting must be submitted by June 23\, 2018. Please apply early\, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed\, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the conference chair if more seats become available due to cancellations. \nGRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above\, any applicants who wish to be considered for an oral presentation should submit their application by April 21\, 2018. Please refer to the application instructions in the Conference Description section below for more details (if available). \nAn outline of the program components for this GRS is displayed below. The seminar chair is currently developing their detailed program schedule\, which will include the speakers they select from submitted abstracts\, in addition to any additional components outlined below. The detailed program will be available by May 21\, 2018. Please check back for updates. \n\nKeynote Speaker\n\n\n\nPetra Hajkova (MRC London Institute of Medical Sciences\, United Kingdom)\n\n\n\nSpeakers\n\n\n\nTo Be Selected from Submitted Abstracts\n\n\n\nDiscussion Leaders\n\n\n\nAna Pombo (Berlin Institute for Medical Systems Biology\, Germany)\nLars Jansen (Instituto Gulbenkian de Ciência\, Fundação Calouste Gulbenkian\, Portugal)\nAlistair Boettiger (Stanford University School of Medicine\, USA)\n\n\n\n\nAdditional Discussion Leaders May Be Selected from Submitted Abstracts\n\n\n\nMentorship Component\n\n\n“The Next Chapter in Chromatin Biology”
URL:https://ces.b2sg.org/event/grs-21jul18/
LOCATION:Grand Summit Hotel at Sunday River\, 97 Summit Road\, Newry\, ME\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/grs_logo_rgb-e1525287092671.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180625
DTEND;VALUE=DATE:20180630
DTSTAMP:20180505T182800Z
CREATED:20180226T213149Z
LAST-MODIFIED:20180505T182800Z
UID:19706-1529884800-1530316799@ces.b2sg.org
SUMMARY:3rd European Summer School on Nutrigenomics
DESCRIPTION:Modulation of the epigenome by nutrition and xenobiotics during early life and across the life span: the key role of life style\nTopics of interest: \n\n-Key role of epigenetics in the programming of adult health\n-How nutrition modulates health through nutrigenomics and nutrigenetics \n-How xenobiotics control gene expression: not just epigenetics  \n-How life style (diet\, physical activity\, sleep\, leisure-time and sedentary behaviour) modifies gene expression \n-Nutrigenomic biomarkers in blood\, urine and saliva\n\nAll participants will acquire 6 CFU/ECTS \nRegistration fees & info: http://d7.unicam.it/nutrigenomics/registration-fees \n  \nCall for grant application (deadline: March 20th\, 2018):  \nhttp://d7.unicam.it/nutrigenomics/call-grant-application \n  \nScientific Committee \nChair: Gabbianelli Rosita\, University of Camerino\, Italy\n De Caterina Raffaele\, G. d’Annunzio” University\, Chieti\, Italy\n Lorenzetti Stefano\, Istituto Superiore di Sanità\, ISS\, Roma\, Italy\n Muller Michael\, University of East Anglia\, Norwich\, United Kingdom\n Nasuti Cinzia\, University of Camerino\, Italy\n Torsten Plosch\, Dept. Obstetrics and Gynaecology\, Groningen\, The Netherlands\n Rots Marianne\, University Medical Center Groningen\, The Netherlands\n  \n Co-organizer\n EpichemBio Cost Action \n  \n Local Organizing Committee\n Chair: Gabbianelli Rosita\n Bordoni Laura\n Fedeli Donatella\n Nasuti Cinzia\n School of Pharmacy\, Università of Camerino\, Camerino\, Italy
URL:https://ces.b2sg.org/event/jesi-25jun18/
LOCATION:3 rd European Summer School on Nutrigenomics\, Jesi\, Italy
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/02/unicam-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180604
DTEND;VALUE=DATE:20180607
DTSTAMP:20180506T134727Z
CREATED:20180506T132708Z
LAST-MODIFIED:20180506T134727Z
UID:20022-1528070400-1528329599@ces.b2sg.org
SUMMARY:Molecular Pathology Approach to Cancer
DESCRIPTION:Molecular pathology is one of the linchpins of precision medicine. No longer can treatment decisions related to therapy selection be rendered solely on the basis of histopathological analyses\, as genomic analyses of human cancers are resulting in the identification of the genetic determinants of tumourigenesis\, cancer progression and therapy response. \nThe pathologists’ role in the implementation of molecular tests in diagnostic practice and the ability of pathology laboratories to perform these tests and communicate the results to oncologists are germane to the successful translation of scientific advancements into benefit to patients. \nThis course aims to provide a comprehensive overview of the state-of-the-art molecular pathology approaches and their application\, and to discuss current genomics and molecular pathology of solid malignancies. \nTarget audience\nThis course will provide a discussion of current concepts in molecular pathology\, molecular pathology methods and their application. It will be beneficial for practicing pathologists and oncologists\, residents and fellows in pathology and oncology\, and molecular biologists with an interest in molecular pathology and precision medicine. \nTopics to be covered\n\nThe role of the pathologist in precision medicine\nMassively parallel sequencing methods and data interpretation\nGene expression regulation\nPlasma circulating cell-free DNA analysis\nPerspectives in molecular testing for clinical decision-making in oncology in Europe and USA\nThe molecular pathology of immunotherapy response\nMolecular pathology of breast cancer and the usefulness of transcriptomic and genomic biomarkers in breast cancer pathology and oncology practice\nNovel findings in ovarian and endometrial cancers\nTargeted therapies in melanoma\nKIT and novel therapeutic targets in gastrointestinal stromal tumours\nGenomics of lung and colorectal cancers\, and the use of genetic biomarkers for therapeutic decision-making\nMolecular classification of sarcomas and central nervous system tumours\n\nKey dates\nBursary application deadline:\n 06 April 2018 \nRegistration deadline:\n 04 May 2018
URL:https://ces.b2sg.org/event/eacr-4jun18/
LOCATION:De Rode Hoed\, Keizersgracht 102\, Amsterdam\, 1015\, Netherlands
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/EACR-new-logo-jpeg-e1526380502516.jpg
ORGANIZER;CN="Laura Strachan (Conference and Ambassador Officer)":MAILTO:l.strachan@nottingham.ac.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180601
DTEND;VALUE=DATE:20180606
DTSTAMP:20180510T231520Z
CREATED:20180510T231359Z
LAST-MODIFIED:20180510T231520Z
UID:20042-1527811200-1528243199@ces.b2sg.org
SUMMARY:ASCO Annual Meeting
DESCRIPTION:The Annual Meeting brings together more than 32\,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities\, new therapies\, and ongoing controversies in the field. \n\n\n\n\n\n\nWe can’t wait to see you in Chicago. As you prepare for this year’s Meeting\, visit the Attendee Resource Center to find a host of resources that will help simplify your experience. Also\, check out pre-meeting educational programs and networking meet-ups and networking lounges designed to help attendees make the most out of their meeting. \n\n\n\nSESSION TYPES\n \n\n\n\n\n\n\n\n\nEducation Sessions\nEducation Sessions offer interdisciplinary or multidisciplinary explorations of focused areas of clinical oncology. ASCO’s Cancer Education Committee determines the topics and format for these sessions that will best serve the educational needs of Annual Meeting attendees. Particular care is taken to ensure that these sessions address issues including surgical\, radiation\, and geriatric oncology; symptom management; health services research; international perspectives; and pathology\, as appropriate. \nClinical Problems in Oncology Sessions\nClinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive keypad technology for audience participation. These sessions are ticketed and require an additional registration fee. \nMeet the Professor Sessions\nMeet the Professor Sessions enable interactive discussion between attendees and recognized experts in a variety of subspecialty fields. The format is informal with an emphasis on a face-to-face exchange with the expert. These sessions are ticketed and require an additional registration fee. \nWorkshops\nNew in 2018: ASCO Annual Meeting Workshops will offer interactive\, didactic teaching to attendees on select topics. Attendees will participate in hands-on experiences\, working in small groups to learn practical\, take-home skills and tools to implement in their practices. Workshops are scheduled for Friday\, June 1\, and will be limited in size. Space will be available on a first come\, first served basis.  \nPlenary Session\nThe Plenary Session includes 15-minute didactic presentations highlighting abstracts of scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field will serve as discussants to place research findings into perspective. The Plenary Session will take place on June 3\, 2018\, 1:00 PM-4:00 PM. \nOral Abstract Sessions\nOral Abstract Sessions include didactic presentations of abstracts representing important clinical and translational research findings by topic category. Presenting authors may use PowerPoint slides to accompany their oral presentation. Experts in the field are chosen as discussants to provide comprehensive themed discussions of the findings from predetermined abstracts. \nClinical Science Symposia\nClinical Science Symposia provide a forum for science in oncology\, providing foundational education on a specific topic with the presentation of abstracts. Experts in the field (discussants) place studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice. \nHighlights of the Day Sessions\nHighlights of the Day Sessions invite expert discussants to present key findings\, put abstracts into clinical context\, and provide an overview of the previous day’s oral abstract sessions. \nPoster and Poster Discussion Sessions\nAbstracts displayed in poster format. Select posters will be chosen for Poster Discussion Sessions where expert discussants will highlight the most clinically applicable and novel posters\, with abstract authors participating as panel members. These sessions will be followed by networking with discussants and authors. \nAward Lectures\nPresented throughout the Annual Meeting\, Award Lectures recognize distinguished award recipients. \nAnnual Business Meeting\nThe ASCO Annual Business Meeting is for ASCO Members to hear updates on the state of the Society.  Members are encouraged to pre-register online to attend this event. \nOpening Session\nThe Opening Session includes the Presidential Address\, Guest Speaker’s Address\, and recognition of Fellows of the American Society of Clinical Oncology (FASCO).
URL:https://ces.b2sg.org/event/asco-1jun18/
LOCATION:ASCO 2018\, McCormick Place\, Chicago\, IL\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/asco.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180323
DTEND;VALUE=DATE:20180328
DTSTAMP:20171001T201229Z
CREATED:20170508T200834Z
LAST-MODIFIED:20171001T201229Z
UID:17907-1521763200-1522195199@ces.b2sg.org
SUMMARY:Chromatin Architecture and Chromosome Organization (X5) in Whistler\, Canada
DESCRIPTION:The meeting will begin on Friday\, March 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday\, March 27 with a closing plenary session from 17:00 to 19:00\, followed by a social hour and entertainment. We recommend return travel on Wednesday\, March 28 in order to fully experience the meeting.  \nSpeakers: \nKaren Adelman\, Harvard Medical School\, USA  \nGeneviève Almouzni\, Centre National de la Recherche Scientifique\, France  \nCheryl Arrowsmith\, University of Toronto\, Canada  \nEmily Bernstein\, Mount Sinai School of Medicine\, USA \nWendy A. Bickmore\, University of Edinburgh\, UK  \nJames E. Bradner\, Novartis Institutes for BioMedical Research\, USA  \nClifford P. Brangwynne\, Princeton University\, USA  \nGiacomo Cavalli\, Institute of Human Genetics\, France  \nIbrahim Cissé\, Massachusetts Institute of Technology\, USA \nVictor G. Corces\, Emory University\, USA  \nPatrick Cramer\, Max Planck Institute for Biophysical Chemistry\, Germany  \nJob Dekker\, University of Massachusetts Medical School\, USA  \nJennifer A. Doudna\, HHMI/University of California\, Berkeley\, USA  \nDenis Duboule\, EPFL-SV-ISREC-UPDUB\, Switzerland  \nJoseph R. Ecker\, The Salk Institute for Biological Studies\, USA  \nRonald M. Evan\, Howard Hughes Medical Institute\, Salk Institute\, USA \nPeter Fraser\, Florida State University\, USA  \nEileen E.M. Furlong\, European Molecular Biology Laboratory\, Germany  \nSusan M. Gasser\, Friedrich Miescher Institute for Biomedical Research\, Switzerland  \nWilliam J. Greenleaf\, Stanford University\, USA  \nMitchell Guttman\, California Institute of Technology\, USA \nSuzana Hadjur\, University College London\, UK \nEdith Heard\, Institut Curie\, France  \nManolis Kellis\, Massachusetts Institute of Technology / Broad Institute\, USA  \nWouter de Laat\, Hubrecht Institute\, Netherlands   \nMichael S. Levine\, Princeton University\, USA  \nRoss L. Levine\, Memorial Sloan Kettering Cancer Center\, USA \nStavros Lomvardas\, Columbia University\, USA  \nMarc A. Marti-Renom\, CNAG-CRG\, Spain  \nLeonid Mirny\, Massachusetts Institute of Technology\, USA  \nStefan Mundlos\, Max Planck Institute for Molecular Genetics\, Germany \nGeeta J. Narlikar\, University of California\, San Francisco\, USA   \nWilliam Stafford Noble\, University of Washington\, USA \nAna Pombo\, Max-Delbrück-Centrum für Molekulare Medizin\, Germany  \nOliver J. Rando\, University of Massachusetts Medical School\, USA  \nKaren L. Reddy\, Johns Hopkins University\, USA  \nBing Ren\, Ludwig Institute for Cancer Research\, USA  \nPeter C. Scacheri\, Case Western Reserve University\, USA  \nPhillip A. Sharp\, Massachusetts Institute of Technology\, USA \nJane A. Skok\, New York University School of Medicine\, USA  \nMikhail Spivakov\, Babraham Institute\, UK  \nJohn A. Stamatoyannopoulos\, University of Washington\, USA  \nBas van Steensel\, Netherlands Cancer Institute\, Netherlands \nAmos Tanay\, Weizmann Institute\, Israel  \nJuanma Vaquerizas\, Max Planck Institute for Molecular Biomedicine\, Germany \nJoanna Wysocka\, Stanford University School of Medicine\, USA  \nRichard A. Young\, Whitehead Institute for Biomedical Research\, USA  \nMagdalena Zernicka-Goetz\, University of Cambridge\, UK  \nLeonard I. Zon\, HHMI/Boston Children’s Hospital\, USA  \n  \nScholarship Deadline: Nov 28\, 2017\n Discounted Abstract Deadline: Nov 28\, 2017\n Abstract Deadline: Dec 20\, 2017\n Discounted Registration Deadline: Jan 17\, 2018 \n  \n 
URL:https://ces.b2sg.org/event/keystone-mar2018/
LOCATION:Whistler Conference Centre\, 4010 Whistler Way\, Whistler\, V0N 1B4\, Canada
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/keystone-e1494159273833.jpg
END:VEVENT
END:VCALENDAR